These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7589338)

  • 41. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
    Kobrinsky NL; Sposto R; Shah NR; Anderson JR; DeLaat C; Morse M; Warkentin P; Gilchrist GS; Cohen MD; Shina D; Meadows AT
    J Clin Oncol; 2001 May; 19(9):2390-6. PubMed ID: 11331317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [MMIP chemotherapy for the treatment of the relapsed and refractory non-Hodgkin's lymphoma].
    Takeshima M; Nakamura S; Mochizuki Y; Hattori N; Kaya H; Otake S; Okabe Y; Okumura H; Yoshida T; Matano S
    Rinsho Ketsueki; 1995 Feb; 36(2):106-14. PubMed ID: 7715081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
    Davidson KL; Devaney MB; Tighe JE; Rogers SY; Dunlop DJ; Mackie MJ; Thomas RV; Johnson PR;
    Haematologica; 2003 Dec; 88(12):1366-71. PubMed ID: 14687989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
    Romaguera JE; Hagemeister FB; McLaughlin P; Rodriguez MA; Bachier C; Preti H; Sarris AH; Weber D; Younes A; Cabanillas F
    Leuk Lymphoma; 1998 Dec; 32(1-2):97-106. PubMed ID: 10037005
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
    Merk K; Ideström K; Johansson B; Kimby E; Lindemalm C; Osby E; Björkholm M
    Eur J Haematol; 1991 Jan; 46(1):33-7. PubMed ID: 1988304
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin.
    Haim N; Rosenblatt E; Wollner M; Ben-Shahar M; Epelbaum R; Robinson E
    Cancer Chemother Pharmacol; 1992; 30(3):243-4. PubMed ID: 1628376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Twin-track studies of ifosfamide and mitoxantrone (I-M) in recurrent high grade non-Hodgkin's lymphoma and Hodgkin's disease. Yorkshire Regional Lymphoma and Central Lymphoma Groups.
    Child JA; Simmons AV; Barnard DL; Parapia L; Morgan M; Grace RJ; Fletcher J; Parker D; Norfolk DR; Stone J
    Hematol Oncol; 1991; 9(4-5):235-44. PubMed ID: 1743626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
    Dinçol D; Içli F; Karaoğuz H; Cay F; Arican A; Demirkazik A; Akbulut H
    Acta Oncol; 1995; 34(7):937-40. PubMed ID: 7492384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
    Gentet JC; Patte C; Quintana E; Bergeron C; Rubie H; Pein F; Demaille MC; Philip T; Raybaud C
    J Clin Oncol; 1990 Apr; 8(4):661-5. PubMed ID: 2313335
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
    Sandlund JT; Pui CH; Mahmoud H; Zhou Y; Lowe E; Kaste S; Kun LE; Krasin MJ; Onciu M; Behm FG; Ribeiro RC; Razzouk BI; Howard SC; Metzger ML; Hale GA; Rencher R; Graham K; Hudson MM
    Ann Oncol; 2011 Feb; 22(2):468-71. PubMed ID: 20624787
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ifosfamide plus mitoxantrone as salvage treatment in non-Hodgkin's lymphomas.
    Lorusso V; Paradiso A; Guida M; Berardi F; De Lena M
    Am J Clin Oncol; 1991 Dec; 14(6):492-5. PubMed ID: 1957837
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Sequential alternating chemotherapy of highly malignant non-Hodgkin's lymphomas with VIM-Bleo and CHOP. Initial results].
    Steinke B; Kraft A; Reinold HM; Heim ME; Löffler B; Heidemann E; Richter C; Josten K; Bross K; Hofmann I
    Onkologie; 1989 Feb; 12(1):19-21. PubMed ID: 2469999
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
    Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
    J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.